Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Secondary exposure to testosterone from patients receiving replacement therapy with transdermal testosterone gels.

Miller MG, Rogol AD, Zumbrunnen TL.

Curr Med Res Opin. 2012 Feb;28(2):267-9. doi: 10.1185/03007995.2011.652255. Epub 2012 Jan 20. No abstract available.

PMID:
22185432
2.

New modalities of transdermal testosterone replacement.

Basaria S, Dobs AS.

Treat Endocrinol. 2003;2(1):1-9. Review.

PMID:
15871550
3.

Treatment options for a patient experiencing pruritic rash associated with transdermal testosterone: a review of the literature.

McGriff NJ, Csako G, Kabbani M, Diep L, Chrousos GP, Pucino F.

Pharmacotherapy. 2001 Nov;21(11):1425-35. Review.

PMID:
11714217
4.

Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption.

Stahlman J, Britto M, Fitzpatrick S, McWhirter C, Testino SA, Brennan JJ, Zumbrunnen TL.

Curr Med Res Opin. 2012 Feb;28(2):291-301. doi: 10.1185/03007995.2011.652732. Epub 2012 Jan 24.

PMID:
22188558
5.

Testosterone replacement therapy for older men.

Wald M, Meacham RB, Ross LS, Niederberger CS.

J Androl. 2006 Mar-Apr;27(2):126-32. Review. No abstract available.

6.
7.

A new testosterone gel (fortesta) for hypogonadism.

[No authors listed]

Med Lett Drugs Ther. 2011 Apr 18;53(1362):29-30. Erratum in: Med Lett Drugs Ther. 2011 May 30;53(1365):44.

PMID:
21502933
8.

Testosterone replacement therapy in male hypogonadism.

Byrne M, Nieschlag E.

J Endocrinol Invest. 2003 May;26(5):481-9. Review.

PMID:
12906378
9.

Transdermal estradiol and testosterone transfer in man: existence, models, and strategies for prevention.

Busse KL, Maibach HI.

Skin Pharmacol Physiol. 2011;24(2):57-66. doi: 10.1159/000321444. Epub 2010 Nov 18. Review.

PMID:
21088452
10.

Reversal of polycythaemia induced by intramuscular androgen replacement using transdermal testosterone therapy.

Siddique H, Smith JC, Corrall RJ.

Clin Endocrinol (Oxf). 2004 Jan;60(1):143-5. No abstract available.

PMID:
14678301
11.

Testosterone treatment comes of age: new options for hypogonadal men.

Nieschlag E.

Clin Endocrinol (Oxf). 2006 Sep;65(3):275-81. Review.

PMID:
16918944
12.

The uses and misuses of testosterone therapy.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2006 Aug;18(6):3, 7. No abstract available.

PMID:
16921650
13.

Testosterone and the primary care physician.

Tomlinson JM.

Int J Clin Pract. 2007 Apr;61(4):538-9. No abstract available.

PMID:
17394425
14.

Testosterone supplementation: what and how to give.

Jockenhövel F.

Aging Male. 2003 Sep;6(3):200-6.

PMID:
14628500
15.

New clinical applications of transdermal testosterone delivery in men and women.

Mazer NA.

J Control Release. 2000 Mar 1;65(1-2):303-15.

PMID:
10699290
16.

Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies.

de Ronde W.

Hum Reprod. 2009 Feb;24(2):425-8. doi: 10.1093/humrep/den372. Epub 2008 Oct 23. Review.

PMID:
18948313
17.

Replacement therapy, not recreational tonic.

Jones RD, Jones TH, Channer KS.

Nature. 2004 Nov 25;432(7016):439. No abstract available.

PMID:
15565127
18.

Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen.

Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA.

Gynecol Endocrinol. 2011 Jan;27(1):39-48. doi: 10.3109/09513590.2010.487597.

PMID:
21142609
19.

Polycythaemia as a complication of transdermal testosterone therapy.

Viallard JF, Marit G, Mercié P, Leng B, Reiffers J, Pellegrin JL.

Br J Haematol. 2000 Jul;110(1):237-8. No abstract available.

PMID:
10931008
20.

Risks of testosterone replacement.

Redmond G.

N Engl J Med. 2004 May 6;350(19):2004-6; author reply 2004-6. No abstract available.

PMID:
15131838

Supplemental Content

Support Center